LAUSANNE, Switzerland – January 27, 2022 – 4:00 pm (CET) – Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, today announced that Alice T. Feng will join the Lunaphore leadership team as Chief Financial Officer, effective January 31, 2022. Ms. Feng brings over two decades of finance and corporate development leadership experience as well as investment banking expertise, participating in over 30 merger and acquisition and financing transactions with aggregate transaction value of $45 billion.

“Alice brings deep expertise in corporate development and the capital markets and will play an instrumental role in our fundraising activities and leading the development of new partnerships as the company continues to expand globally,” said Ata Tuna Ciftlik, Ph.D., Chief Executive Officer of Lunaphore. “We are excited to work with Alice to achieve Lunaphore’s ambitious goals as we bring spatial biology into the mainstream.”

Ms. Feng most recently served as Chief Financial Officer of Scripps Research, a world-renowned biomedical research institution in San Diego, California. In this role, Ms. Feng was an instrumental member of the executive team that supported all of Scripps’ financial strategy and operations. She joined as Senior Director of Corporate Development and Finance in 2017.

Prior to joining Scripps Research, Ms. Feng worked with Scripps Health and Aetna, as the Senior Director of Corporate Development, where she led all aspects of M&A including due diligence, deal structure, valuation and negotiation. Prior to that, she spent over 11 years in investment banking, initially with a bulge-bracket firm, Merrill Lynch, and later with a boutique investment bank, Morgan Joseph.

Ms. Feng has long been passionate about healthcare. She received a B.S. in Business Economics and Microbiology and Molecular Genetics from the University of California, Los Angeles, and worked in academic research laboratories studying genetics as well as volunteering in local hospitals.

“I am particularly excited to join the Lunaphore team and help lead the company during this important stage of growth,” said Ms. Feng. “I look forward to raising Lunaphore’s financial profile as it executes on its vision of making spatial biology methods accessible to researchers around the world.”

 

To learn more about Lunaphore, please visit: https://lunaphore.com/

 

About Lunaphore

Lunaphore Technologies S.A. is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore has developed a game-changing chip technology which can extract spatial proteomic and genomic data from tumors and transform any simple assay into multiplex spatial biology without complexity. Lunaphore empowers researchers to push the boundaries of research to ultimately develop the next generation personalized therapies. For further information on Lunaphore and its products, please visit www.lunaphore.com.

 

 

For further information contact:

 

Irene Tamayo

Lunaphore Corporate Communications

Email: [email protected]

 

 

LAUSANNE, Switzerland – January 19, 2022 – 12:00 pm (CET) – Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, today announced the appointment of Janis M. Taube, M.D., M.Sc., a leading pathologist and expert on immunotherapy research, to its Scientific Advisory Board. As an advisor, Dr. Taube will provide strategic advisory support to Lunaphore’s scientific activities and product portfolio development.

“Janis is a trailblazer and highly regarded expert in pathology and immunotherapy research, and we are excited to work with her to build visibility of our products in laboratories around the world,” said Diego G. Dupouy, Ph.D., Chief Technology Officer of Lunaphore. “We are proud to have convened a world-class group of scientific advisors to help advance our scientific and product development strategy.”

Dr. Taube is the Director of the Dermatopathology division of Johns Hopkins Hospital in Baltimore, MD. She also serves as a Professor of Dermatology, Professor of Oncology, and Professor of Pathology at the Johns Hopkins University School of Medicine. Dr. Taube holds additional roles as Co-Director of the Tumor Microenvironment Laboratory at the Bloomberg~Kimmel Institute for Cancer Immunotherapy as well as Co-Director of the Mark Foundation Center for Advanced Genomics and Imaging.

Her research primarily focuses on immune evasion by solid tumors—specifically studying the PD-1/PD-L1 axis—and the identification of potential biomarkers that predict response to novel immunotherapies. She developed the PD-L1 immunohistochemical assay and scoring system for the first in-human anti-PD-1 and anti-PD-L1 clinical trials, versions of which are now FDA approved and mainstays of cancer treatment.

“I firmly believe that the next generation of biomarkers will involve spatially resolved and quantitative analysis of the immunological landscape of tumors,” said Dr. Taube.

Dr. Taube earned an M.D. at Tulane University School of Medicine and completed her residency in anatomic pathology at Johns Hopkins University School of Medicine. She completed a fellowship in dermatopathology at Stanford University School of Medicine.

 

To learn more about Lunaphore, please visit: https://lunaphore.com/

 

Disclaimer: 

¹ Participation by Janis Taube as an advisor to Lunaphore does not constitute or imply endorsement of Lunaphore by Johns Hopkins University.

 

About Lunaphore

Lunaphore Technologies S.A. is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore has developed a game-changing chip technology which can extract spatial proteomic and genomic data from tumors and transform any simple assay into multiplex spatial biology without complexity. Lunaphore empowers researchers to push the boundaries of research to ultimately develop the next generation personalized therapies. For further information on Lunaphore and its products, please visit www.lunaphore.com.

 

For further information contact:

 

Irene Tamayo

Lunaphore Corporate Communications

Email: [email protected]

LAUSANNE, Switzerland – November 18, 2021 – 11:00 pm (CET) – Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, today announced the events and activities planned around the inaugural Lunaphore Spatial Biology Week™, taking place virtually December 6-10, 2021. The five-day online meeting will highlight how new technology solutions are lowering the barriers for adoption of spatial biology technologies in a wide range of research laboratories in hospitals, academia, core facilities and the biopharmaceutical industry. Registration is free and open to researchers from Europe and North America.

During the meeting, scientific experts at prominent industry and academic research institutions will discuss real-world applications of spatial biology methods to advance research in immuno-oncology, pathology, immunology, and infectious diseases, among other fields. Confirmed speakers include:

 

• Dr. Charlotte Stadler, Head of the National Spatial Proteomics Facility, SciLifeLab (Sweden)
• Dr. Alexander Klimowicz, Senior Principal Scientist, Boehringer Ingelheim Pharmaceuticals (USA)¹
• Dr. Matthew Pugh, MRC Clinical Research Training Fellow, University of Birmingham (UK)
• Dr. Inti Zlobec, Head of the Translational Research Unit (TRU), University of Bern (Switzerland)
• Dr. Andrew Janowczyk, Assistant Research Professor, Department of Biomedical, Engineering, Case School of Engineering (USA)

 

 

Event Overview:

• Monday, December 6: From protein to RNA analysis: educational series on spatial biology
• Tuesday, December 7: From hypothesis to screening: spatial proteomics day
• Wednesday, December 8: From fundamental to translational research: spatial biology for all laboratories
• Thursday, December 9: The future of spatial biology
• Friday, December 10: Spatial biology: workshops and user-dedicated sessions

 

To register and learn more about the event, please visit: https://lunaphore.com/resource-center/webinars/the-spatial-biology-week/

 

To learn more about Lunaphore, please visit: www.lunaphore.com

 

Disclaimer:

¹ This is the sole opinion of Dr. Alexander Klimowicz based on his personal experience with different multiplex immunohistochemistry platforms. The presentation does not represent any official endorsement by Boehringer Ingelheim.

 

About Lunaphore

Lunaphore Technologies S.A. is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore has developed a game-changing chip technology which can extract spatial proteomic and genomic data from tumors and transform any simple assay into multiplex spatial biology without complexity. Lunaphore empowers researchers to push the boundaries of research to ultimately develop the next generation personalized therapies. For further information on Lunaphore and its products, please visit www.lunaphore.com.

 

 

For further information contact:

Irene Tamayo

Lunaphore Corporate Communications

Email: [email protected]

 

 

LAUSANNE, Switzerland – November 9, 2021 – 2:00 pm (CET) – Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, today announced new research from collaborators at the University of Birmingham, who characterized the inflammatory response associated with a complication from maternal COVID-19 infection, using COMET™, Lunaphore’s all-in-one staining and imaging platform for high-throughput, hyperplex immunofluorescence. The results will be presented at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting, taking place November 10-14, 2021 virtually and in-person at the Walter E. Washington Convention Center in Washington, D.C. Lunaphore will also hold product demonstrations of LabSat® and COMET™ at booth #408.

Using spatial biology tools to characterize COVID-19 placentitis

A proportion of maternal COVID-19 infections are complicated by COVID-19 placentitis, an inflammatory response that often leads to fetal death. However, there has been limited research to-date on the processes that drive this condition and its underlying pathology.

In a sponsored symposium, Matthew Pugh, FRCPath, of the University of Birmingham will discuss how his team used the Lunaphore COMET™ system to conduct a multiplex immunohistochemistry analysis of 30 markers to characterize the processes that drive COVID-19 placentitis. Utilizing spatial biology methods, the present study found that COVID-19 placentitis is characterized by direct infection of the villous trophoblast, histiocytic intervillousitis and associated CXCL10 & interferon mediated inflammation¹.

 

Read the full abstract here and view the presentation details below.

 

Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting: The morpho-molecular features of COVID-19 placentitis:  A high dimensional, multi-omic approach

Date and time: Saturday, November 13; 1:30 – 2:00 p.m. EST | 7:30 – 8:00 p.m. CET

Speaker: Matthew Pugh, FRCPath (Institute of Immunology and Immunotherapy, University of Birmingham)

 

In-booth product demonstrations

Lunaphore will also feature its LabSat® and COMET™ spatial biology solutions at booth #408. Live product demonstrations will take place:

• Friday, November 12; 1:30 – 2:00 p.m. and 6:00-6:30 p.m. EST
• Saturday, November 13; 1:00 – 1:30 p.m. and 6:00-6:30 p.m. EST

 

To learn more about LabSat®, please visit: https://lunaphore.com/products/labsat/.

To learn more about COMET™, please visit: https://lunaphore.com/products/comet/.

To find out more about Lunaphore’s activities on site, please visit:  https://lunaphore.com/news/lunaphore-at-sitc-annual-meeting/.

 

Disclaimer:

¹ The research is not yet published or peer-reviewed.

 

 

About Lunaphore

Lunaphore Technologies S.A. is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore has developed a game-changing chip technology which can extract spatial proteomic and genomic data from tumors and transform any simple assay into multiplex spatial biology without complexity. Lunaphore empowers researchers to push the boundaries of research to ultimately develop the next generation personalized therapies. For further information on Lunaphore and its products, please visit www.lunaphore.com.

 

For further information contact:

 

Irene Tamayo

Lunaphore Corporate Communications

Email: [email protected]

LAUSANNE, Switzerland – October 14, 2021 – 4:00 pm (CEST) – Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, today announced it will host a virtual scientific talk in partnership with Labroots on October 21, 2021, about spatial “omics” methods as a laboratory service. Dr. Charlotte Stadler, Head of the National Spatial Proteomics Facility and platform coordination officer for the Spatial and Single Cell Biology Platform at SciLifeLab, a world-renowned institute in Sweden focused on the advancement of molecular biosciences, will discuss the incorporation of spatial proteomics technologies in service laboratory workflows. The talk will focus on how her facility is utilizing COMET™, Lunaphore’s all-in-one staining and imaging platform for high-throughput, hyperplex immunofluorescence, to explore the cellular landscape across several tissue types.

In the webinar, Dr. Stadler will discuss multiplexed spatial proteomics using sequential immunofluorescence and show results obtained with COMET™. The Spatial and Single Cell Biology (SSCB) platform at SciLifeLab expects to fully integrate COMET™ into its workflow and offer it as a service next year.

“The COMET™ system allows for systematic development of multiplexed panels for a variety of tissues,” said Dr. Stadler. “Using sequential indirect immunofluorescence, one’s existing set of validated primary antibodies can be optimized and used in a multiplexed manner.”

“Our work with SciLifeLab to integrate COMET™ into their service laboratory workflows is a key step in our mission to bring spatial biology into every laboratory,” said Déborah Heintze, Co-Founder and Chief Marketing Officer at Lunaphore. “We are excited to work with Dr. Stadler and her team as they implement COMET™ for large-scale use.”

Learn more about the event and register here.

 

PRESENTATION DETAILS

Including Spatial Proteomics in your research – why and how

Date and time: Thursday, October 21, 2021; 4:00 pm CEST / 7:00 am PT / 10:00 am ET

Speaker: Dr. Charlotte Stadler, Head of the National Spatial Proteomics Facility (Stockholm, Sweden)

 

Disclaimer:

The TMA and antibodies were provided by Atlas Antibodies.

 

About Lunaphore

Lunaphore Technologies S.A. is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore has developed a game-changing chip technology which can extract spatial proteomic and genomic data from tumors and transform any simple assay into multiplex spatial biology without complexity. Lunaphore empowers researchers to push the boundaries of research to ultimately develop the next generation personalized therapies. For further information on Lunaphore and its products, please visit www.lunaphore.com.

 

For further information contact:

 

Irene Tamayo

Lunaphore Corporate Communications

Email: [email protected]

 

 

The TOP 25 Scale-Ups list recognizes the most promising Swiss companies with the greatest potential for further growth. To acknowledge the success and potential of companies aged from 5 and up to 10 years, the growth jury was asked to select the TOP 25 scale-ups.

After finishing on the podium of the TOP100 Swiss Start-Ups Award in 2019 and being highlighted in the Top25 Swiss Scale-ups in 2020, we are happy to announce that Lunaphore is one more time among the best scale-ups of 2021.

Read the news here

Today, Lunaphore is pleased to welcome Diane Castex de la Guéronnière as Vice President of Human Resources. In her new role, Diane will lead the Lunaphore HR team and elevate Lunaphore’s talent to fuel the company’s next phase of growth.

“I am truly amazed by Diane’s executive mindset; leadership blended with perpetual positive energy and unique successful track record in growing global”, noted Dr. Ciftlik, Lunaphore’s CEO. “She will definitely be the perfect HR business partner to our teams to fuel Lunaphore’s skyrocket growth ahead.”

Diane has over 15 years of expertise leading and building HR teams and recruitment capabilities at technology-driven companies. Diane joined Lunaphore from Nexthink, where she was Director of International HR and created its HR department, supporting the company’s global expansion from 80 to over 650 employees in over 15 locations around the world.

Prior to joining Nexthink, Diane was Manager at Michael Page, where she successfully established Michael Page’s first Swiss office in Geneva. After serving as onsite recruiter for various international companies, Diane served as EMEA Recruitment Manager at Lifesize, a U.S.-based video conferencing company and a branch of Logitech Lifesize Communications.

“I’ve always been motivated by mission-driven companies, and Lunaphore is no exception. Lunaphore has massive business potential, being the gamechanger in what spatial biology looks like in today’s world, said Diane. “I know happy employees are key to a company’s success. Therefore, my mission is simply to create the best employee experience ever.”

Diane earned a Master in Sales Administration and completed the Leadership Development Journey at IMD Business School in Switzerland. She is also part of the Accredited Coaching Training Program from the International Coaching Certification (ICF).